slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
215,041-215,100 of 319,975
03
The slide uses a simple icon-based list to communicate high-level corporate strategy.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations 1 hit
04
The slide uses a frequency spectrum diagram to visualize the specific band NextNav occupies.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · Problem1 hit
05
PNT stands for Positioning, Navigation, and Timing.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
06
The slide uses a logo grid to establish credibility and market presence.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
07
NextNav | Investor Presentation Deck | 10 slidesNextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
08
The slide details a capital raise structure involving senior secured notes and warrants.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
09
The slide uses a hub-and-spoke diagram to present six key investment pillars.NextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations Beat · The Ask1 hit
10
NextNav | Investor Presentation Deck | 10 slidesNextNav | Investor Presentation Deck | 10 slides · NextNav
Pitch deck Investor relations 1 hit
01
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Attention1 hit
02
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Attention1 hit
03
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Attention1 hit
04
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Attention1 hit
05
The slide uses a split layout with a bulleted list of achievements on the left and visual branding/map on the right.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
06
The slide uses a map of California to visualize station locations and a table to provide granular project details.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
07
The slide highlights a specific operational deployment plan for 9 mobile fuelers.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
08
Slide 8 of a presentation, likely Nikola Corporation.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Pattern Hunter1 hit
09
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Loop · Pattern Hunter1 hit
10
Includes footnotes regarding restricted cash, FFI acquisition, share registration, and adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
11
Includes footnotes detailing stock-based compensation components.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
12
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
13
Includes footnotes regarding order conditions and currency units.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Pattern Hunter1 hit
14
The slide contains only a high-quality photograph of the product and the company logo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
15
Nikola | Results Presentation Deck | 19 slidesNikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
16
Includes a footnote regarding adjustments for Q4 2022 and Q1 2023.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
17
The table includes a footnote regarding adjustments for Romeo.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
18
The table includes a footnote regarding Q4 2022 and Q1 2023 adjustments related to Romeo Power.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
19
The slide is a full-bleed image of the product with the company logo in the bottom right corner.Nikola | Results Presentation Deck | 19 slides · Nikola
Conference presentation Investor relations Beat · Action1 hit
01
Features company logo, date, and a molecular structure visualization.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
03
The slide uses a visual bracket system to connect the three pillars to the core mission statement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
04
The slide combines a retrospective traction report with a mission/vision statement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
06
Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
09
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · Competitive AnalysisLoop · Cost Of Inaction1 hit
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
The slide uses dot plots for IC50 data and a bar chart for tumor regression efficacy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a bar chart to compare brain penetrance and a grouped bar chart to show selectivity indices across multiple drugs.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
20
Clinical trial data presentation for NVL-520.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
22
The chart is a swimmer plot (a common clinical trial visualization).Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
23
Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
24
Includes patient case study images and clinical trial metrics.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
Slide 26 of a clinical presentation.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a list of icons to represent key features of the drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
The slide outlines the key therapeutic advantages of the drug candidate NVL-330.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit